Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
BR112016026842A2 - preparação compreendendo fator viii e peptídeos de fator de von willebrand - Google Patents
[go: Go Back, main page]

BR112016026842A2 - preparação compreendendo fator viii e peptídeos de fator de von willebrand - Google Patents

preparação compreendendo fator viii e peptídeos de fator de von willebrand

Info

Publication number
BR112016026842A2
BR112016026842A2 BR112016026842A BR112016026842A BR112016026842A2 BR 112016026842 A2 BR112016026842 A2 BR 112016026842A2 BR 112016026842 A BR112016026842 A BR 112016026842A BR 112016026842 A BR112016026842 A BR 112016026842A BR 112016026842 A2 BR112016026842 A2 BR 112016026842A2
Authority
BR
Brazil
Prior art keywords
von willebrand
factor
preparation
peptides
willebrand factor
Prior art date
Application number
BR112016026842A
Other languages
English (en)
Inventor
Solecka Barbara
Kannicht Christoph
Kohla Guido
Winge Stefan
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octapharma Ag filed Critical Octapharma Ag
Publication of BR112016026842A2 publication Critical patent/BR112016026842A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção refere-se à composição que compreende um complexo do fator viii e um ou mais peptídeos do fator de von willebrand, em que os peptídeos do fator de von willebrand compreendem pelo menos os aminoácidos 764 a 1035 e 1691 a 1905 do seq id no. 1, mas não aminoácidos 2255 a 2645 do seq id no. 1.
BR112016026842A 2014-06-06 2015-06-08 preparação compreendendo fator viii e peptídeos de fator de von willebrand BR112016026842A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14171579 2014-06-06
PCT/EP2015/062730 WO2015185758A2 (en) 2014-06-06 2015-06-08 Preparation comprising factor viii and von willebrand factor peptides

Publications (1)

Publication Number Publication Date
BR112016026842A2 true BR112016026842A2 (pt) 2017-12-12

Family

ID=50884302

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016026842A BR112016026842A2 (pt) 2014-06-06 2015-06-08 preparação compreendendo fator viii e peptídeos de fator de von willebrand

Country Status (13)

Country Link
US (1) US10251940B2 (pt)
EP (2) EP3360895B1 (pt)
JP (1) JP6605593B2 (pt)
KR (1) KR20170010895A (pt)
CN (1) CN106414492B (pt)
AU (1) AU2015270394B2 (pt)
BR (1) BR112016026842A2 (pt)
CA (1) CA2949323A1 (pt)
DK (2) DK3360895T3 (pt)
ES (2) ES2895798T3 (pt)
IL (1) IL249294A0 (pt)
RU (1) RU2714154C2 (pt)
WO (1) WO2015185758A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3400002T3 (da) * 2016-01-07 2022-04-11 CSL Behring Lengnau AG Muteret, trunkeret von willebrand faktor
EP3458085B1 (en) 2016-05-20 2022-12-07 Octapharma AG Glycosylated vwf fusion proteins with improved pharmacokinetics
SG11201903954WA (en) 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
ES2966835T3 (es) 2017-06-22 2024-04-24 CSL Behring Lengnau AG Modulación de la inmunogenicidad del FVIII por VWF truncado
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
US20220305089A1 (en) 2019-08-16 2022-09-29 Octapharma Ag Stabilizing buffer for factor viii and vwf
KR20250168493A (ko) 2023-03-31 2025-12-02 옥타파마 아게 개선된 약동학을 갖는 fviii-vwf 융합 단백질
WO2025181343A1 (en) 2024-02-29 2025-09-04 Octapharma Ag Cystine knot domain fusion protein dimers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
JP2010529155A (ja) * 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのｖｗｆ安定化ｆｖｉｉｉ製剤及びｆｖｉｉｉなしのｖｗｆ製剤の使用
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
MX2011001624A (es) 2008-08-21 2011-03-28 Octapharma Ag Factor viii y ix humano producido en forma recombinante.
WO2011020866A2 (en) 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
DK2467399T3 (en) * 2009-08-20 2017-01-23 Baxalta Inc Purification of vWF for increased removal of non-lipid-enveloped viruses
WO2013057167A1 (en) 2011-10-18 2013-04-25 Csl Behring Gmbh Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
WO2013160005A1 (en) * 2012-04-24 2013-10-31 Novo Nordisk A/S Pharmaceutical composition suitable for treatment of haemophilia
JP2015515482A (ja) * 2012-04-24 2015-05-28 ノヴォ ノルディスク アー／エス 血友病の治療に適する化合物

Also Published As

Publication number Publication date
CN106414492B (zh) 2021-07-06
DK3152230T3 (da) 2019-11-11
EP3152230A2 (en) 2017-04-12
RU2016152151A3 (pt) 2019-02-06
US10251940B2 (en) 2019-04-09
CN106414492A (zh) 2017-02-15
AU2015270394A1 (en) 2016-11-24
ES2747815T3 (es) 2020-03-11
IL249294A0 (en) 2017-02-28
EP3360895A3 (en) 2018-10-17
AU2015270394B2 (en) 2017-12-21
US20180185455A1 (en) 2018-07-05
DK3360895T3 (da) 2021-11-15
JP6605593B2 (ja) 2019-11-13
RU2016152151A (ru) 2018-07-10
EP3360895B1 (en) 2021-08-11
JP2017518376A (ja) 2017-07-06
KR20170010895A (ko) 2017-02-01
EP3152230B1 (en) 2019-08-07
ES2895798T3 (es) 2022-02-22
CA2949323A1 (en) 2015-12-10
WO2015185758A3 (en) 2016-02-11
WO2015185758A2 (en) 2015-12-10
RU2714154C2 (ru) 2020-02-12
EP3360895A2 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
MX2017004559A (es) Receptores de celulas t.
CL2021000716A1 (es) Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269)
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
MX2022011309A (es) Receptores de celulas t.
CL2018002825A1 (es) Vacuna contra vrs
MX2018012268A (es) Receptores de celulas t.
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
MX2018012265A (es) Receptores de celulas t.
BR112016026773A2 (pt) domínios variáveis de imunoglobulina aperfeiçoados
MX373035B (es) Trastornos neurodegenerativos.
BR112018074032A2 (pt) composições e métodos relacionados a construtos de fc manipulados
BR112017020308A2 (pt) udp-glicosiltransferases
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
BR112019004911A2 (pt) oligonucleotídeos modificados e métodos de uso
WO2015179635A3 (en) Ras inhibitory peptides and uses thereof
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
BR112018013246A2 (pt) rótulo de peptídeo e proteína rotulada incluindo o mesmo
BR112016016103A2 (pt) Composição de antígenos micobacterianos
PH12019501064A1 (en) Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
CU24609B1 (es) Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic
MX2018003445A (es) Expresion de proteinas que contienen fc.
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
MX420767B (es) Proteina de union al factor h modificada
BR112018003580A2 (pt) molécula de ácido nucléico, método para apresentar um polipeptídeo alvo, proteína recombinante, partícula do tipo viral, composição farmacêutica, polipeptídeo, vetor, célula hospedeira e método para preparar a proteína recombinante

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements